Mitral-valve repair versus replacement for severe ischemic mitral regurgitation.

Published

Journal Article

Ischemic mitral regurgitation is associated with a substantial risk of death. Practice guidelines recommend surgery for patients with a severe form of this condition but acknowledge that the supporting evidence for repair or replacement is limited.We randomly assigned 251 patients with severe ischemic mitral regurgitation to undergo either mitral-valve repair or chordal-sparing replacement in order to evaluate efficacy and safety. The primary end point was the left ventricular end-systolic volume index (LVESVI) at 12 months, as assessed with the use of a Wilcoxon rank-sum test in which deaths were categorized below the lowest LVESVI rank.At 12 months, the mean LVESVI among surviving patients was 54.6±25.0 ml per square meter of body-surface area in the repair group and 60.7±31.5 ml per square meter in the replacement group (mean change from baseline, -6.6 and -6.8 ml per square meter, respectively). The rate of death was 14.3% in the repair group and 17.6% in the replacement group (hazard ratio with repair, 0.79; 95% confidence interval, 0.42 to 1.47; P=0.45 by the log-rank test). There was no significant between-group difference in LVESVI after adjustment for death (z score, 1.33; P=0.18). The rate of moderate or severe recurrence of mitral regurgitation at 12 months was higher in the repair group than in the replacement group (32.6% vs. 2.3%, P<0.001). There were no significant between-group differences in the rate of a composite of major adverse cardiac or cerebrovascular events, in functional status, or in quality of life at 12 months.We observed no significant difference in left ventricular reverse remodeling or survival at 12 months between patients who underwent mitral-valve repair and those who underwent mitral-valve replacement. Replacement provided a more durable correction of mitral regurgitation, but there was no significant between-group difference in clinical outcomes. (Funded by the National Institutes of Health and the Canadian Institutes of Health; ClinicalTrials.gov number, NCT00807040.).

Full Text

Duke Authors

Cited Authors

  • Acker, MA; Parides, MK; Perrault, LP; Moskowitz, AJ; Gelijns, AC; Voisine, P; Smith, PK; Hung, JW; Blackstone, EH; Puskas, JD; Argenziano, M; Gammie, JS; Mack, M; Ascheim, DD; Bagiella, E; Moquete, EG; Ferguson, TB; Horvath, KA; Geller, NL; Miller, MA; Woo, YJ; D'Alessandro, DA; Ailawadi, G; Dagenais, F; Gardner, TJ; O'Gara, PT; Michler, RE; Kron, IL; CTSN,

Published Date

  • January 2014

Published In

Volume / Issue

  • 370 / 1

Start / End Page

  • 23 - 32

PubMed ID

  • 24245543

Pubmed Central ID

  • 24245543

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

International Standard Serial Number (ISSN)

  • 0028-4793

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1312808

Language

  • eng